Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Iberdomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 24 Jan 2025 New trial record